Trial Profile
A Phase 2 Trial for Patients With Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide, and BMX-001
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs BMX 001 (Primary)
- Indications Glioma
- Focus Therapeutic Use
- Acronyms BMX-HGG
- Sponsors BioMimetix
- 17 Nov 2023 Results presented in the BioMimetix media release.
- 17 Nov 2023 According to a BioMimetix media release, data were presented from its Phase 2 study of lead candidate, BMX-001, for the treatment of high-grade glioma (HGG) at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting. The abstract will be published in SNO official journal, Neuro-Oncology.
- 26 Oct 2023 According to a BioMimetix media release, data from its Phase 2 study of lead candidate, BMX-001, for the treatment of high-grade glioma (HGG), has been selected as a late breaking oral presentation at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting taking place on November 15-19, 2023 in Vancouver, Canada.